Trillium reports Phase I data for TTI-621 in DLBCL

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported data from 18 evaluable patients with diffuse large B cell lymphoma (DLBCL) in the dose-expansion portion of the Phase Ia/Ib TTI-621-01 trial showing that IV TTI-621 (SIRPaFc, SIRPalphaFc) as monotherapy or with Rituxan rituximab led to two complete responses and three partial responses, plus six cases of stable disease. TTI-621 was well tolerated. Data were presented at the American Society of Hematology meeting in Atlanta.

Patients received TTI-621 weekly starting at 0.2 mg/kg as monotherapy or 0.1 mg/kg when given with Rituxan. The primary endpoint is safety. The open-label, North American trial has enrolled 89 patients, and expects to enroll about 270 patients with relapsed or refractory hematologic malignancies and solid tumors...